Your browser doesn't support javascript.
loading
A review of the totality of evidence in the development of ABP 798, a rituximab biosimilar.
Cobb, Patrick; Niederwieser, Dietger; Cohen, Stanley; Hamm, Caroline; Burmester, Gerd; Seo, Neungseon; Lehto, Sonya G; Hanes, Vladimir.
Afiliação
  • Cobb P; St Vincent Frontier Cancer Center, Billings, MT 59102, USA.
  • Niederwieser D; Division of Hematology and Oncology, University of Leipzig, Leipzig, Liebigstr. 19, 04106, Germany.
  • Cohen S; Metroplex Clinical Research Center, Dallas, TX 75231, USA.
  • Hamm C; Windsor Oncology; Western University; Windsor, ON N8W2X3, Canada.
  • Burmester G; Department of Rheumatology & Clinical Immunology, Free University & Humboldt University Berlin, Charité-University Medicine Berlin, Charitéplatz 1, Berlin, 10117, Germany.
  • Seo N; Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320-1799, USA.
  • Lehto SG; Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320-1799, USA.
  • Hanes V; Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320-1799, USA.
Immunotherapy ; 14(9): 727-740, 2022 06.
Article em En | MEDLINE | ID: mdl-35543293
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Artrite Reumatoide / Medicamentos Biossimilares Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Artrite Reumatoide / Medicamentos Biossimilares Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article